US2015320727A1PendingUtilityA1
Heterocyclic compounds and uses thereof
Est. expiryAug 17, 2029(~3.1 yrs left)· nominal 20-yr term from priority
A61P 7/00A61P 37/02A61P 43/00A61P 9/00A61P 9/10A61P 7/04A61P 37/08A61P 35/04A61P 3/10A61P 37/06A61P 35/00A61P 31/12A61P 25/00A61P 3/00A61P 27/02A61P 25/04A61P 29/02A61P 29/00A61P 25/14A61P 25/02A61P 25/28A61P 31/04A61P 11/08A61P 1/18A61P 19/02A61P 13/12A61P 1/16A61P 11/00A61P 11/06A61P 1/04A61P 13/08A61P 15/08A61P 21/00A61P 19/00A61P 17/02A61P 17/06A61P 1/00A61P 17/00A61P 15/00A61P 17/16C07D 401/14C07D 413/14C07D 519/00A61K 31/541A61K 31/497A61K 31/4709A61K 31/498A61K 31/428A61K 31/422A61K 31/423A61K 31/517C07D 417/04C07D 487/04A61K 31/444C07D 413/04A61K 31/496C12N 9/1205A61K 31/5377C07D 471/04A61K 31/437A61K 31/551A61K 31/5025C07D 417/14C07D 519/06Y02A50/30
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Claims
exact text as granted — not AI-modified1 .- 53 . (canceled)
54 . A method of treating a disorder associated with PI3 kinase comprising administering to a subject in need thereof a compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein
W 1 is CR 3 ;
W 2 is CR 4 ;
W 3 is N;
W 4 is N;
W 5 is CR 7 ;
W 6 is CR 8 ;
R 1 and R 2 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate,
R 3 is amido of formula —C(O)N(R) 2 , or —NHC(O)R, wherein R is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heteroalicyclic; or wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered ring, and
R 4 , R 7 and R 8 are each hydrogen.
55 . The method of claim 54 , wherein R 1 is hydrogen and R 2 is amino.
56 . The method of claim 55 , wherein R 2 is NH 2 .
57 . The method of claim 54 , wherein R 3 is amido of formula —C(O)N(R) 2 wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered ring.
58 . The method claim 57 , wherein R 1 is hydrogen and R 2 is amino.
59 . The method claim 58 , wherein R 2 is NH 2 .
60 . The method of claim 59 , wherein R 3 is amido of formula —C(O)N(R) 2 wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 6-membered ring.
61 . The method of claim 60 , wherein the compound is
or pharmaceutically acceptable salt.
62 . The method of claim 54 , wherein the compound or pharmaceutically acceptable salt is
63 . The method of claim 54 , wherein the disorder is asthma, emphysema, bronchitis, psoriasis, allergy, anaphylaxis, rheumatoid arthritis, graft versus host disease, lupus erythematosus, psoriasis, restenosis, benign prostatic hypertrophy, diabetes, pancreatitis, proliferative glomerulonephritis, diabetes-induced renal disease, inflammatory bowel disease, atherosclerosis, eczema, scleroderma, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma, or ovarian, breast, lung, pancreatic, prostate, colon, gastric or epidermoid cancer.
64 . The method of claim 63 , wherein the disorder is lung cancer.
65 . The method of claim 64 , wherein the lung cancer is non-small cell lung cancer.
66 . The method of claim 64 , wherein the lung cancer is small cell lung cancer.
67 . The method of claim 63 , wherein the disorder is gastric cancer
68 . The method according to any one of claim 63 , 64 , 65 , 66 or 67 , wherein the compound is
or pharmaceutically acceptable salt.
69 . A method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase) comprising: contacting the PI3 kinase with a compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein
W 1 is CR 3 ;
W 2 is CR 4 ;
W 3 is N;
W 4 is N;
W 5 is CR 7 ;
W 6 is CR 8 ;
R 1 and R 2 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate,
R 3 is amido of formula —C(O)N(R) 2 or —NHC(O)R, wherein R is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heteroalicyclic; or wherein said (R) 2 groups taken together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, or 7-membered ring, and
R 4 , R 7 and R 8 are each hydrogen.
70 . The method of claim 69 , wherein the compound is
or pharmaceutically acceptable salt.
71 . The method of claim 69 wherein said step of contacting comprises contacting a cell that expresses said PI3 kinase.
72 . The method of claim 69 wherein the PI3 kinase is PI3 kinase alpha.
73 . The method of claim 69 comprising administering a second therapeutic agent to the cell.
74 . The method of claim 69 wherein the contacting step takes place in vivo.
75 . The method of claim 69 wherein the contacting step takes place in vitro.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.